Literature DB >> 11099463

The VMAT2 gene in mice and humans: amphetamine responses, locomotion, cardiac arrhythmias, aging, and vulnerability to dopaminergic toxins.

G R Uhl1, S Li, N Takahashi, K Itokawa, Z Lin, M Hazama, I Sora.   

Abstract

Monoamine compartmentalization in monoaminergic neurons uses serial action of the plasma membrane and vesicular monoamine (VAMT2) transporters. We can now define the sequences of the genes encoding these transporters in mice and humans, examine influences of deletions of this gene and alteration in its expression levels in transgenic mice, and identify sequence polymorphisms in the human VMAT2 gene. Examination of VMAT2 variants can provide potential insights into roles for allelic variants at these loci in variant drug responses and in diseases linked to monoaminergic systems, including substance abuse and Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11099463     DOI: 10.1096/fj.00-0205rev

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  18 in total

Review 1.  VMAT2: a dynamic regulator of brain monoaminergic neuronal function interacting with drugs of abuse.

Authors:  Lee E Eiden; Eberhard Weihe
Journal:  Ann N Y Acad Sci       Date:  2011-01       Impact factor: 5.691

2.  Perinatal heptachlor exposure increases expression of presynaptic dopaminergic markers in mouse striatum.

Authors:  W Michael Caudle; Jason R Richardson; Minzheng Wang; Gary W Miller
Journal:  Neurotoxicology       Date:  2005-08       Impact factor: 4.294

3.  Reduced vesicular storage of catecholamines causes progressive degeneration in the locus ceruleus.

Authors:  Tonya N Taylor; Shawn P Alter; Minzheng Wang; David S Goldstein; Gary W Miller
Journal:  Neuropharmacology       Date:  2013-09-08       Impact factor: 5.250

4.  Deletion of Go2alpha abolishes cocaine-induced behavioral sensitization by disturbing the striatal dopamine system.

Authors:  Irene Brunk; Christian Blex; Carles Sanchis-Segura; Jan Sternberg; Stephanie Perreau-Lenz; Ainhoa Bilbao; Heide Hörtnagl; Jens Baron; Judyta Juranek; Gregor Laube; Lutz Birnbaumer; Rainer Spanagel; Gudrun Ahnert-Hilger
Journal:  FASEB J       Date:  2008-07-07       Impact factor: 5.191

Review 5.  Genetic factors modulating the response to stimulant drugs in humans.

Authors:  Amy B Hart; Harriet de Wit; Abraham A Palmer
Journal:  Curr Top Behav Neurosci       Date:  2012

6.  Gain-of-function haplotypes in the vesicular monoamine transporter promoter are protective for Parkinson disease in women.

Authors:  Charles E Glatt; Angelika D Wahner; Daniel J White; Andres Ruiz-Linares; Beate Ritz
Journal:  Hum Mol Genet       Date:  2005-12-08       Impact factor: 6.150

Review 7.  The role of oxidative stress in Parkinson's disease.

Authors:  Vera Dias; Eunsung Junn; M Maral Mouradian
Journal:  J Parkinsons Dis       Date:  2013       Impact factor: 5.568

8.  VMAT1 deletion causes neuronal loss in the hippocampus and neurocognitive deficits in spatial discrimination.

Authors:  P K Multani; R Hodge; M A Estévez; T Abel; H Kung; M Alter; B Brookshire; I Lucki; A H Nall; K Talbot; G A Doyle; F W Lohoff
Journal:  Neuroscience       Date:  2012-11-29       Impact factor: 3.590

Review 9.  Implications of genome wide association studies for addiction: are our a priori assumptions all wrong?

Authors:  F Scott Hall; Jana Drgonova; Siddharth Jain; George R Uhl
Journal:  Pharmacol Ther       Date:  2013-07-18       Impact factor: 12.310

10.  Genomewide discovery and classification of candidate ovarian fertility genes in the mouse.

Authors:  Teresa D Gallardo; George B John; Lane Shirley; Cristina M Contreras; Esra A Akbay; J Marshall Haynie; Samuel E Ward; Meredith J Shidler; Diego H Castrillon
Journal:  Genetics       Date:  2007-07-29       Impact factor: 4.562

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.